BioNTech Falls Short In Jittery IPO Market
Investors also readjust to firm's unproven pipeline
After ADC Therapeutics
You may also be interested in...
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.